Alexion Pharmaceuticals, Inc

Add to watchlist
€152.5
Last updated:07/20/2021
AXP: F
Alexion Pharmaceuticals, Inc

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS for the treatment of PNH, aHUS, generalized m… Show more

P/E ratio
58.36x
vs. 13.62x forward

Price is 58.36x times more than EPS €2.61 which eaquals €152.5

Stock volatility (Beta)
past 12 months

Become our supporter to unlock all data!
Company results
Quarterly
Annual
Fundamentals
2017
2018
2019
2020
Net Income
Income minus expenses, depreciation, interest, taxes, and other expenses
Create free account to unlock
Cashflow
Sum up money going in and out company
Create free account to unlock
Total liabilities
All combined debts and obligations
Create free account to unlock
Company profile
CEO
Dr. Ludwig N. Hantson
Market capitalization
Mega (34.45B)